Association of survival and plasma levels of cardiac biomarkers in patients with ATTR using unadjusted log-rank test.

<p>Survival stratified by combination of troponin T/I cut-off values as well as NT-proBNP/BNP quartiles cut-off values (A) in the whole cohort; (B) in patients with wildtype ATTR; (C) in patients with mutant type ATTR; (D) in patients with Val30Met; (E) in patients with early onset of Val30Met; (F) in patients with late onset of Val30Met; (G) in patients with non-Val30Met; (H) in patients with Val122Ile. <i>P</i>-values are for the comparison between the combination of patients with values above vs. below the cut-off value. Stage A: both natriuretic peptides AND troponins above; Stage B both natriuretic peptides AND troponins below; Stage C: either of the natriuretic peptides OR troponins is above.</p

Association of survival and plasma levels of natriuretic peptides in patients with ATTR using unadjusted log-rank test.

<p>Survival stratified by natriuretic peptides (BNP/NT-proBNP) optimal cut-off values (A) in the whole cohort; (B) in patients with wildtype ATTR; (C) in patients with mutant type ATTR; (D) in patients with Val30Met; (E) in patients with early onset of Val30Met; (F) in patients with late onset of Val30Met; (G) in patients with non-Val30Met; (H) in patients with Val122Ile. <i>P</i>-values are for the comparison between the combination of above vs. below the cut-off value.</p

Unadjusted comparison of cardiac biomarkers in patients with ATTR by genotype, mutation, and age at disease onset.

<p>(A) BNP in patients with wild type (WT) vs. mutant type (MT); (B) NT-proBNP in patients with WT vs. MT; (C) Troponin I in patients with WT vs. MT; (D) Troponin T in patients with WT vs. MT; (E) BNP in patients with Val30Met vs. non-Val30Met mutations; (F) NT-proBNP in patients with Val30Met vs. non-Val30Met mutations; (G) Troponin I in patients with Val30Met vs. non-Val30Met mutations; (H) Troponin T in patients with Val30Met vs. non-Val30Met mutations; (I) BNP in patients with early vs. late onset of ATTR due to Val30Met mutation; (J) NT-proBNP in patients with early vs. late onset of ATTR due to Val30Met mutation; (K) Troponin I in patients with early vs. late onset of ATTR due to Val30Met mutation; (L) Troponin T in patients with early vs. late onset of ATTR due to Val30Met mutation.</p

Demographics of patients according to the combined quartiles of cardiac biomarkers.

<p>Demographics of patients according to the combined quartiles of cardiac biomarkers.</p

Demographics of symptomatic patients.

<p>Demographics of symptomatic patients.</p

Correlations of biomarkers with clinical and echocardiographic parameters.

<p>Correlations of biomarkers with clinical and echocardiographic parameters.</p

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: an Analysis from the Transthyretin Amyloidosis Outcome Survey (THAOS)

<p></p><p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>.</b> <a href="https://link.springer.com/article/10.1007/s40120-018-0097-9">https://link.springer.com/article/10.1007/s40120-018-0097-9</a></p><p></p><p></p><p> </p><p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p><br><p></p

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>.</b> <a href="https://link.springer.com/article/10.1007/s40120-016-0040-x">https://link.springer.com/article/10.1007/s40120-016-0040-x</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p